Friday, August 04, 2023 10:59:47 AM
REPORT #30 (2023) For Week Ending 7/28/2023.
Thanks once again to @rafunrafun for providing the script data.
The Takeaway: It’s a slow progression, but VASCEPA® is gradually increasing week/week, month/month and Quarter/Quarter against Generic VASCEPA® and Generic Lovaza.
• Slide #1: The Gap between Generic Lovaza and VASCEPA® continues to narrow.
• Slide #2: VASCEPA® trending up vs. GV trending down while total mkt curves up.
• Slide #3: Historical timeline of events vs. quarterly scripts. A 2023 reversal?
• Slide #4: Head-to Head V vs. GV
• Slide #5: VASCEPA® slowing gaining share each month vs. GV
• Slide #6: VASCEPA® slowing gaining share each month vs. GLV
• Slide #7: Individual product shares for WE 7/28/23
• Slide #8: Individual product percent and absolute changes week/week.
you can find this week’s Report (07/21/2023) here.
https://drive.google.com/file/d/1IDVKTNy3XpNdtDmITbVqzF8VXRa-8pqq/view?usp=sharing
Recent AMRN News
FEATURED Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
